By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A*STAR Institute of Microelectronics today announced it has signed an agreement to advance QuantuMDx's DNA sequencing nanowire biosensor to the point of commercialization.

QMDx, based in the UK, is developing a handheld all-in-one DNA sequencer, which is currently in prototype. The collaboration leverages Singapore-based A*STAR's silicon-based nanowire technology to develop technology for the simultaneous detection of large numbers of difference cells and biomaterials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.